Extended Anticoagulation with Reduced-Dose Non-inferior to Full-Dose Apixaban for the Prevention of Recurrent VTE in Patients with Active Cancer By Ogkologos - April 29, 2025 852 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the API-CAT study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR News digest – HPV vaccine, 1 million breast screenings missed and... October 3, 2020 FDA Approves Daratumumab plus Hyaluronidase-fihj, Carfilzomib, and Dexamethasone for Relapsed or... December 2, 2021 What Caregivers Should Know About End-of-Life Care Issues for People With... September 8, 2022 She Faced Breast Cancer At 16 With Little Help From Doctors.... June 21, 2019 Load more HOT NEWS The Growths On This Woman’s Lips Are A Sign That She... ESMO Congress 2022, 9-13 September Tucatinib Added to Trastuzumab and Capecitabine Continues to Demonstrate a Significant... Liquid Biopsies for Cancer: What to Know and What to Expect
